VALNValneva SE

Nasdaq valneva.com


$ 8.41 $ 1.04 (13.84 %)    

Monday, 19-Aug-2024 12:27:33 EDT
QQQ $ 480.40 $ -0.90 (-0.19 %)
DIA $ 409.09 $ 2.37 (0.58 %)
SPY $ 559.11 $ 5.30 (0.96 %)
TLT $ 98.30 $ 0.00 (0 %)
GLD $ 231.62 $ -0.38 (-0.16 %)
$ 8.56
$ 7.65 x 100
-- x --
-- - --
$ 6.39 - $ 14.94
32,592
na
-6
$ 2.13
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-reaffirmed-its-2024-guidance-expects-total-revenues-of-170m-190m-and-rd-investments-between-60m-75m

Full-year 2024 Financial Guidance Confirmed Expected total revenues between €170 million and €190 million, including €160 mi...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 valneva-and-limmatech-forge-strategic-partnership-to-fast-track-development-of-leading-tetravalent-shigella-vaccine

Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 cepi-and-eu-grant-valneva-413m-to-enhance-global-reach-of-chikungunya-vaccine-ixchiq

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ® Fun...

 pfizervalnevas-vaccine-study-for-tick-borne-infection-completes-primary-vaccination-series-plans-approval-in-2026

Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease...

Core News & Articles

Participants completed primary vaccination series (3 doses) with VLA15 Primary vaccination series to be followed by a booster a...

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

 hc-wainwright--co-reiterates-buy-on-valneva-maintains-26-price-target

HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.

Core News & Articles

Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical tria...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION